Showing 4081-4090 of 8877 results for "".
- ARCADIA 1 and 2: Nemolizumab Reduces Itch, Sleep Disturbance in Atopic Dermatitishttps://practicaldermatology.com/news/arcadia-nemolizumab-reduces-itch-sleep-disturbance-in-atopic-dermatitis/2462226/Nemolizumab, an interleukin-31 (IL-31) receptor alpha antagonist, demonstrated significant efficacy in adults and adolescents with atopic dermatitis (AD) in a pair of identical trials, according to new study results pre
- For Alopecia Areata, Discontinuation of Baricitinib Linked with Loss of Benefithttps://practicaldermatology.com/news/for-alopecia-areata-discontinuation-of-baricitinib-linked-with-loss-of-benefit/2462225/Results from a randomized substudy of the BRAVE-AA1 study suggested that patients with severe alopecia areata who withdrawal from treatment with baricitinib also lose the treatment benefit.
- Interim Analysis: Tralokinumab Improves Quality of Life in Moderate-to-Severe Atopic Dermatitishttps://practicaldermatology.com/news/interim-analysis-tralokinumab-improves-quality-of-life-in-moderate-to-severe-atopic-dermatitis/2462224/Tralokinumab, an interleukin-13 (IL-13) inhibitor approved for the treatment of moderate-to-severe atopic dermatitis (AD) in adults, was shown to improve several quality of life measures, a 6-month interim analysis sugg
- Long-Term Analysis Shows Upadacitinib Safe Up to 5 Years for Moderate to Severe ADhttps://practicaldermatology.com/news/long-term-analysis-shows-upadacitinib-safe-up-to-5-years-for-moderate-to-severe-ad/2462222/Upadacitinib for the treatment of moderate-to-severe atopic dermatitis (AD) was shown to have an acceptable safety profile at 5 years, according to a new integrated analysis.
- Deucravacitinib Shows Sustained Response, Safety Profile: Analyseshttps://practicaldermatology.com/news/deucravacitinib-shows-sustained-response-safety-profile-analyses/2462221/Deucravacitinib (SOTYKTU, Bristol Myers Squibb) is a first-in-class, oral, selective allosteric TYK2 inhibitor, and has been approved in the United States, European Union, and other countries for use in adults with mode
- BE HEARD Analysis: Bimekizumab Maintains Treatment Response at 48 Weeks in HShttps://practicaldermatology.com/news/be-heard-analysis-bimekizumab-maintains-treatment-response-at-48-weeks-in-hs/2462220/A pooled analysis of data from the BE HEARD I and BE HEARD II trials presented at Maui Derm 2024 suggested adults with moderate-to-severe hidradenitis suppurativa (HS) treated with bimekizumab (BKZ) saw a sustained clin
- Important FDA Approvals in 2023 Lead to New, Exciting Treatments in 2024https://practicaldermatology.com/news/important-fda-approvals-in-2023-lead-to-new-exciting-treatments-in-2024/2462219/A slew of big approvals for new therapies in 2023 has increased the armamentarium for dermatologists treating many conditions going into 2024, according to an opening presentation at Maui Derm 2024. <
- Analysis: Women, Minorities Underrepresented in Psoriasis Researchhttps://practicaldermatology.com/news/analysis-women-minorities-underrepresented-in-psoriasis-research/2462215/A new analysis suggested that women and minorities are consistently underrepresented in the psoriasis and hidradenitis suppurativa (HS) medical literature. "Ensuring clinical trial populations reflect the racial, ethnic, and sex makeup of patient populations is important for
- New Assessment Tool for Chronic Prurigo Shows Power of Patient Reportinghttps://practicaldermatology.com/news/development-and-validation-of-a-patient-reported-outcome-measure-to-assess-disease-control-in-chronic-prurigo/2462214/Researchers have introduced a 5-item Prurigo Control Test (PCT), in what could be the first patient-reported outcome measure for determining disease control for chronic prurigo (CPG). This tool, according to the researchers, was designed to assess disease control in CPG
- Insufficient Disease Control in Moderate-to-Severe AD: Year-long Longitudinal Study Reveals Treatment Gapshttps://practicaldermatology.com/news/insufficient-disease-control-in-severe-atopic-dermatitis-a-12-month-longitudinal-study-reveals-treatment-gaps/2462212/A recent study presented at the Revolutionizing Atopic Dermatitis (RAD) Virtual Conference highlighted has shed light on the persistent issue of therapeuti